-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 30, the first China (Macao) International High-quality Consumer Expo and Hengqin World Bay Area Forum series of activities were officially opened
.
The forum was guided by the Macao SAR Government, the People's Government of Guangdong Province, the State-owned Assets Supervision and Administration Commission of the State Council, the Liaison Office of the Central People's Government in the Macao SAR and the China Council for the Promotion of International Trade.
As one of the sub-forums of the Hengqin World Bay Area Forum, guided by Southern Finance All Media Group and hosted by 21st Century Business Herald and 21st Century New Health Research Institute, the "First Hengqin World Bay Area Forum Biomedical Forum and 2022 China Health Industry Summit" was held, inviting representatives of regulators, industry experts, industry leaders, investment institutions and other parties to focus on the theme of "innovative and high-quality development accelerates the internationalization of medicine", deeply focusing on the great changes in China's medical and health industry.
The Bay Area biomedical industry cluster, the survival and development of innovative pharmaceutical enterprises, the construction of a "healthy Bay Area" and other topics were exchanged and discussed to explore the future
.
At the meeting, the 21st Century New Health Research Institute released the "China Digital Healthcare Industry Development Trend Report (2022 Edition)" and the "Healthy China 21CC Cancer Concern" excellent case selection results
.
At the meeting, the honorary list of "sunshine" cases in the 2022 21st century health industry competitiveness research was also released
.
The list mainly includes categories such as "benchmark enterprises", "enterprises", "people", "public welfare" and "products"
.
Yu Xiaona, member of the editorial board of Southern Finance All-Media Group and member of the editorial board of 21st Century Business Herald, said in her speech that China's pharmaceutical and health industry is currently in a golden age
of sailing.
In recent years, with the comprehensive and in-depth implementation of the "Healthy China" strategy, China has gradually established a scientific supervision system for the whole life cycle, guided by clinical needs, the review and approval process has been accelerating, and biomedicine has become the fastest growing field
in the current pharmaceutical and health industry.
Gui Yi, Director of the Development Planning Division of the Planning Information Department of the National Health Commission, said in his speech that Hengqin is one of the major platforms specified in the Outline Development Plan for the Guangdong-Hong Kong-Macao Greater Bay Area, with unique location advantages, intensive capital and talents, and undertaking major tasks such as building a traditional Chinese medicine science and technology industrial park, and will surely become a display window and test field
to promote the high-quality development of local pharmaceutical products and go to the world.
Li Shiyan, Deputy Director General of the Macao Pharmaceutical Administration, said that Macao is relatively rich in medical resources and has a wide
range of imported drugs and medical devices.
It is hoped that through the establishment of the system, it will provide a legal basis for the development of Macao's small-scale medical device industry, attract enterprises to settle in Macao and the Co-operation Zone, and grasp the unique advantages of Macao and the development opportunities
of the Co-operation Zone construction.
Liang Yun, deputy director of the administrative licensing department of the Guangdong Provincial Food and Drug Administration, said that from the current implementation of the "Hong Kong and Macao Pharmaceutical and Equipment Exchange", there are still four outstanding problems
, such as the need to further optimize and simplify the review and approval process, the strong demand for expanding the scope of designated medical institutions, the slow start of real-world research and construction, and the accessibility of drugs and devices to be improved 。 In the next step, we plan to further improve the regulatory mechanism around these issues, implement the responsibilities of all parties, assist in the determination of the list of the second batch of designated medical institutions, promote the launch of special commercial insurance of the "Hong Kong and Macao Pharmaceutical and Equipment Connect", promote the work of "Macao New Neighborhood", timely update the catalogue of Hong Kong and Macao drugs and medical devices urgently needed for clinical needs in the Guangdong-Hong Kong-Macao Greater Bay Area, and promote the real-world research and construction of
the Guangdong-Hong Kong-Macao Greater Bay Area.
(End)
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
